A clinical trial showed that Johnson & Johnson’s COVID-19 vaccine is 66 percent effective at preventing moderate to severe disease, the company said Friday. That level of protection came 28 days after vaccination, according to data from a global phase 3 trial. Onset of protection was observed as early as day 14. The level rose to 72 percent in the United States. It was 66 percent in Latin American and just 57 percent in South Africa. The double blind, placebo-controlled trial included 43,783 patients. Of those, 468 accrued symptomatic cases of COVID-19, the disease caused by the CCP (Chinese Communist Party) virus. “Johnson & Johnson embarked on the global effort to combat the COVID-19 pandemic a year ago, and has brought the full force of our capabilities, as well as tremendous public-private partnerships, to enable the development of a single-shot vaccine. Our goal all along has been to create a simple, …